Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2+ or ER+ Locally Advanced or Metastatic Breast Cancer Patients

Novartis Investigative Site, Bellinzona

Georgia Health Sciences University Med College of GA, Augusta

Washington University School Of Medicine-Siteman Cancer Ctr Dept. of Siteman Cancer Ctr., St Louis

Cancer Therapy & Research Center / UT Health Science Center InstituteForDrugDevelopment(3), San Antonio

Nevada Cancer Institute Clinical Trials Office, Las Vegas

UCLA/ University of California Los Angeles UCLA, Los Angeles

Dana Farber Cancer Institute StudyCoordinator:CAUY922A2101, Boston

MD Anderson Cancer Center/University of Texas Thoractic Head/Neck Med.Onc(2), Houston

Novartis Investigative Site, Groningen

Novartis Investigative Site, Sutton